Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Entrada Therapeutics, Inc.
NASDAQ:TRDAHealthcare · Biotechnology
+3.07%$4.54
AH$4.59+1.21%vs close
Mkt Cap$176.58M
Float29.6M
O/S38.94M
Vol
$ Vol
RVOL
Inst Own74.7%
SI11.1%
Earnings
Dilution
Financials Summary
Revenue$25.42M
Net Income-$143.75M
Total Assets$377.38M
Free Cash Flow-$129.55M
Debt & Equity
Debt 14%
Equity 86%
Total Debt$50.93M
Total Equity$306.13M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in TRDA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$377.38M
Liabilities$71.25M
Accounts Receivable$2.58M
Accounts Payable$2.29M
Inventory$0
PP&E (Net)$67.76M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $25.42M | $210.78M | $129.01M | $0 | $0 | $0 | $0 |
| YoY Growth | -87.9% | 63.4% | - | - | - | - | - |
| Cost of Revenue | $4.1M | $0 | $0 | $0 | $0 | $326K | $104K |
| Gross Profit | $21.32M | $210.78M | $129.01M | $0 | $0 | -$326K | -$104K |
| Gross Margin | 83.9% | 100.0% | 100.0% | - | - | - | - |
| Research and Development | $142.27M | $125.31M | $99.88M | $66.61M | $35.93M | $21.1M | $8.22M |
| Selling, General, and Administrative | $41.05M | $38.47M | $32.29M | $30.64M | $15.2M | $5.24M | $3.61M |
| Other | -$6M | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $177.32M | $163.77M | $132.18M | $97.25M | $51.13M | $26.34M | $11.82M |
| Operating Income (EBIT) | -$156M | $47.01M | -$3.16M | -$97.25M | -$51.13M | -$26.67M | -$11.82M |
| Operating Margin | -613.7% | 22.3% | -2.5% | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $2.63M | $0 | $0 | $0 |
| Interest Income | $0 | $19.47M | $15.22M | $2.63M | $0 | $0 | $0 |
| Other Income (Expense) | $13.17M | $19.47M | $15.22M | $2.63M | -$31K | $144K | $6.72M |
| Income Before Tax (EBT) | -$142.83M | $66.48M | $12.06M | -$94.62M | -$51.16M | -$26.52M | -$5.1M |
| Income Tax Expense | $924K | $859K | $18.74M | $0 | $0 | $0 | $0 |
| Net Income | -$143.75M | $65.63M | -$6.68M | -$94.62M | -$51.16M | -$26.52M | -$4.65M |
| Net Income Margin | -565.5% | 31.1% | -5.2% | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -3.47 | 1.76 | -0.20 | -2.79 | -1.60 | -0.84 | -4.44 |
| Diluted EPS | -3.47 | 1.68 | -0.20 | -2.79 | -1.60 | -0.84 | -4.44 |
| Weighted Average OS | 41.37M | 37.31M | 33.05M | 31.29M | 31.22M | 31.25M | 1.05M |
| EBITDA | -$138.73M | $70.26M | $14.9M | -$90.09M | -$50.04M | -$26.2M | -$11.72M |
| EBITDA Margin | -545.7% | 33.3% | 11.5% | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $90.39M | $101.21M | $67.6M | $45.16M | $291.06M | $39.05M | $16.84M |
| Short-Term Investments | $205.3M | $318.79M | $284.37M | $143.56M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $295.7M | $420M | $351.97M | $188.71M | $291.06M | $39.05M | $16.84M |
| Accounts Receivable | $2.58M | $3.68M | $5.88M | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $7.98M | $16.36M | $11.92M | $21.16M | $0 | $0 | $0 |
| Total Current Assets | $306.25M | $440.04M | $369.77M | $209.88M | $298.7M | $39.95M | $17.44M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $67.76M | $82.05M | $92.68M | $33.02M | $6.26M | $3.04M | $801K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $3.36M | $4.23M | $6.74M | $9.16M | $872K | $541K | $0 |
| Total Long-Term Assets | $71.13M | $86.28M | $99.42M | $42.18M | $7.13M | $3.58M | $801K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $377.38M | $526.32M | $469.19M | $252.06M | $305.83M | $43.53M | $18.24M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $2.29M | $4.26M | $3.28M | $5.99M | $706K | $1.6M | $710K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $667K | $4.02M | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $342K | $13.65M | $132.26M | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $9.22M | $8.43M | $7.66M | $5.49M | $4.56M | $1.6M | $937K |
| Total Current Liabilities | $24.45M | $39.48M | $158.8M | $21.97M | $6.72M | $3.36M | $1.92M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $6.51M | $7.71M | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $396K | $81.66M | $31.84M |
| Total Long-Term Liabilities | $46.79M | $58.16M | $68.04M | $17.53M | $396K | $81.66M | $31.84M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $71.25M | $97.64M | $226.83M | $39.5M | $7.12M | $85.02M | $33.76M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $4K | $4K | $3K | $3K | $3K | $0 | $0 |
| Retained Earnings | -$273.09M | -$129.34M | -$194.97M | -$188.28M | -$93.67M | -$42.51M | -$15.99M |
| Comprehensive Income & Other | $652K | -$43K | $195K | -$2.06M | $0 | $0 | $0 |
| Other Stockholders' Equity | $579.22M | $558.02M | $437.33M | $400.84M | $392.38M | $1.02M | $470K |
| Total Equity | $306.13M | $428.68M | $242.36M | $212.55M | $298.72M | -$41.49M | -$15.52M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $377.38M | $526.32M | $469.19M | $252.06M | $305.83M | $43.53M | $18.24M |
| Supplementary Data | |||||||
| Total Debt | $50.93M | $59.21M | $68.23M | $25.94M | $0 | $0 | $0 |
| Net Debt | -$39.46M | -$42M | $628K | -$19.22M | -$291.06M | -$39.05M | -$16.84M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$143.75M | $65.63M | -$6.68M | -$94.62M | -$51.16M | -$26.52M | -$5.1M |
| Depreciation & Amortization | $4.1M | $3.77M | $2.84M | $1.9M | $1.12M | $326K | $104K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $19.61M | $17.91M | $13.11M | $9.89M | $2.53M | $325K | $294K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $2.5M | $2.2M | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$1.8M | $991K | -$2.81M | $5.29M | -$715K | $631K | $367K |
| Other Working Capital | -$5.5M | -$122.04M | $139.12M | -$16.4M | -$2.71M | -$349K | -$193K |
| Total Working Capital Change | -$4.8M | -$118.85M | $136.31M | -$11.11M | -$3.42M | $282K | $174K |
| Other Non-Cash Items | -$3.67M | -$10.02M | -$5.78M | $151K | $74K | $20K | -$6.27M |
| Net Cash from Operating | -$128.51M | -$41.56M | $139.8M | -$93.79M | -$50.86M | -$25.57M | -$10.8M |
| Investing Activities | |||||||
| Capital Expenditures | -$1.04M | -$3.16M | -$5.61M | -$2.89M | -$4.58M | -$2.32M | -$630K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$141.61M | -$437.72M | -$407.21M | -$221.98M | $0 | $0 | $0 |
| Sales of Investments | $259.46M | $413.08M | $274.43M | $76.21M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $116.81M | -$27.8M | -$138.4M | -$148.65M | -$4.58M | -$2.32M | -$630K |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | - |
| Common Stock Issuance | $887K | $99.61M | $19.41M | $479K | $190.69M | $0 | $38K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $3.36M | $1.63M | $0 | $939K | $247K | $0 |
| Net Cash from Financing | $887K | $102.96M | $21.04M | $479K | $307.46M | $50.09M | $38K |
| Forex Effect | $0 | $0 | $0 | -$3.95M | $0 | $0 | $28.24M |
| Net Change in Cash | -$10.82M | $33.61M | $22.45M | -$245.91M | $252.02M | $22.2M | $16.84M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$128.51M | -$41.56M | $139.8M | -$93.79M | -$50.86M | -$25.57M | -$10.8M |
| Capital Expenditure | -$1.04M | -$3.16M | -$5.61M | -$2.89M | -$4.58M | -$2.32M | -$630K |
| Free Cash Flow | -$129.55M | -$44.72M | $134.19M | -$96.67M | -$55.44M | -$27.89M | -$11.43M |
| Cash at Beginning | $105.16M | $71.55M | $49.11M | $291.06M | $39.05M | $16.84M | $0 |
| Cash at End | $94.34M | $105.16M | $71.55M | $45.16M | $291.06M | $39.05M | $16.84M |